MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.anpedi.2016.03.014

Медицинская библиотека · Anales de pediatria (Barcelona, Spain : 2003) · 2016

[Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre].

García Morin Marina, Cela Elena, Garrido Carmen, Bardón Cancho Eduardo, Aguado Del Hoyo Alejandra, Pascual Cristina, Pérez-Corral Ana, Beléndez Cristina

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Sickle cell disease (SCD), despite the improvement in the medical management, is still associated with severe morbidity and decreased survival. Allogenic hematopoietic stem cell transplantation (Allo-HSCT) currently provides the only curative therapy. A report is presented on our experience in children with SCD, who underwent Allo-HSCT in a single centre.

MATERIAL AND METHOD: A single centre descriptive study was conducted on patients with SCD who underwent a bone marrow transplant from an HLA-identical sibling donor between January 2010 and December 2014. Epidemiological, clinical and analytical parameters were collected with a follow-up to December 2015. Data are presented as frequencies, percentages, and medians (range).

RESULTS

Allo-HCST was performed in 11 patients (8 males) with a median age of 7 years (2-13), all of them with comorbidity prior to the HCST. A stable graft was achieved in 10 out of 11 patients, 9 of them with complete donor chimerism, and one patient with stable mixed chimerism after 1 year of allo-HSCT. One patient has secondary graft failure with re-appearance of symptoms associated with SCD on day 180. Complications of Allo-HSCT are: arterial hypertension 7/11, acute renal failure 3/11, CMV reactivation 9/11, neurological complications 4/11 (subarachnoid haemorrhage, seizure), and acute graft versus host disease (aGVHD) of the skin 6/11, one of whom developed grade iv intestinal aGVHD, causing his death (day 51). None of the patients developed chronic GVHD. The overall survival and event-free survival was 90.9% and 81.9%, respectively, with a median follow-up of 3.1 (1-5.7) years.

CONCLUSIONS

Allo-HSCT, the only curative therapy, remains associated with morbidity. There was a transplant related mortality in our study, consistent with multicentre studies (1/11), and with aGVHD being the main cause. Other problems still include graft failure (1/11), and neurological complications (4/11), although the permanent sequelae are mild.

Для цитирования: García Morin Marina, Cela Elena, Garrido Carmen, Bardón Cancho Eduardo, Aguado Del Hoyo Alejandra, Pascual Cristina, Pérez-Corral Ana, Beléndez Cristina. [Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre].. Anales de pediatria (Barcelona, Spain : 2003). 2016. DOI: 10.1016/j.anpedi.2016.03.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.